Company: MDCXW
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001062993-25-015839
Chunk: 2

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-29
Form: S-1
Chunk 2
---
 Pharma Ltd. (the “Company”), no par value (the “common shares”), by YA II PN, Ltd. (the “Selling Shareholder” or “Yorkville”). The common shares being offered by this prospectus consist of common shares that we have issued or that we may, in our discretion, elect to issue and sell to the Selling Shareholder, from time to time, pursuant to a standby equity purchase agreement we entered into with the Selling Shareholder on February 10, 2025 (the “SEPA”), pursuant to which the Selling Shareholder has committed to purchase from us, at our direction, up to $15.0 million of common shares (approximately $9.9 million of which remains available), subject to terms and conditions specified in the SEPA. As consideration for the Selling Shareholder’s irrevocable commitment to purchase our common shares at our election and in our discretion from time to time after the date of the SEPA and prior to the third anniversary of the SEPA, upon the terms and subject to the satisfaction of the conditions set forth in the SEPA, we have issued to the Selling Shareholder 105,840 common shares pursuant to the terms of the SEPA (the “Commitment Shares”). As of September 26, 2025, we have issued 2,152,672 common shares to the Selling Shareholder at our direction, excluding the Commitment Shares, for gross proceeds to the Company of approximately $5.1 million.

We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of our common shares by the Selling Shareholder. However, we may receive up to $15,000,000 aggregate gross proceeds from sales of common shares we may elect to make to Yorkville pursuant to the SEPA prior to or after the date of this prospectus. See "Standby Equity Purchase Agreement" on page 132 of this prospectus for a description of the SEPA and "Selling Shareholder" on page 136 of this prospectus for additional information regarding the Selling Shareholder.

The Selling Shareholder may sell or otherwise dispose of the common shares described in this prospectus in a number of different ways and at varying prices. The Selling Shareholder is an "underwriter" within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the "Securities Act"), only with respect to advances under the SEPA and any profits on the sales of our common